ShuoMaMDPhD

Oncology • Chicago, IL

Hematologic Oncology

Professor of Medicine, Hematology/Oncology, Northwestern University Feinberg School of Medicine

Join to view full profile

Dr. Ma is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ma's full profile

Already have an account?

Office
675 N Saint Clair St
Galter 21-100
Chicago, IL 60611
Phone+1 312-695-0990

Fax+1 312-695-1106

Summary

Shuo Ma, MD, PhD is a Chicago-based hematologist-oncologist specializing in lymphoid malignancies with over a decade of experience. She undertook her residency in internal medicine at Ascension Illinois/Saint Joseph and pursued a fellowship in hematology and medical oncology at the McGaw Medical Center of Northwestern University. Dr. Ma also holds a PhD in Cell and Molecular Biology from Northwestern University. She currently serves as a Professor of Medicine at Northwestern University. Dr. Ma's clinical practice and clinical research focus on chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenstrom macroglobulinemia, and other non-Hodgkin lymphomas. She has contributed to the medical literature with publications on hematology and oncology. She has also participated in clinical trials related primarily to CLL/SLL and lymphoma. Additionally, in 2011, she received the Meaningful Use Stage 1 Certification from the Centers for Medicare & Medicaid Services.

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2005 - 2008
Ascension Illinois/Saint Joseph (Chicago)Residency, Internal Medicine, 2002 - 2005
Brigham and Women's HospitalPost-Doctoral Fellowship, 2000 - 2002
Northwestern UniversityPhD, Cell and Molecular Biology, 1994 - 2000
Beijing Medical UniversityClass of 1994

Certifications & Licensure

IL State Medical License 2004 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Castle Connolly Top Doctor Castle Connolly, 2022-2025
Top Doctors in Chicago Chicago Magazine, 2023-2024
Castle Connolly Exceptional Women in Medicine Castle Connolly, 2022-2024
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Join now to see all

Clinical Trials

Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL Start of enrollment: 2005 Apr 14
Completed
Phase 2
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Start of enrollment: 2010 Apr 26
Completed
Phase 1
Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia Start of enrollment: 2011 Jun 01
Active, not recruiting
Phase 2
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Start of enrollment: 2013 Mar 05
Terminated
Phase 1, Phase 2
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2013 Oct 01
Active, not recruiting
Phase 1
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma Start of enrollment: 2013 Dec 01
Completed
Phase 2
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
Active, not recruiting
Phase 3
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Start of enrollment: 2014 Jul 07
Completed
Phase 3
Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Start of enrollment: 2024 Mar 29
Withdrawn
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

B-ALL in a 21-year-old male with X-linked agammaglobulinemia (XLA): a case report and review of B-cell malignancies in XLA.
Stephanie Franco, Joseph Fuchs, Shira Dinner, Shuo Ma
Leukemia & Lymphoma. 2024-12-13
Correction to: "Accelerated" chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): unraveling the biological gray zone of CLL/SLL in the era of novel ther...
Brian Vadasz, Taylor Zak, Jonathan Aldinger, Madina Sukhanova, Juehua Gao
Virchows Archiv. 2024-11-09
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
Nirav N Shah, Michael Wang, Lindsey E Roeker, Krish Patel, Jennifer A Woyach
Haematologica. 2024-10-03

Abstracts/Posters

A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Shuo Ma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas
Shuo Ma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients ...
Shuo Ma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Na¥ve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)
Shuo Ma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation
Shuo Ma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation
Shuo Ma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Press Mentions

Modern COVID-19 Vaccine May Be More Effective for Cancer PatientsApril 29th, 2022
Moderna’s COVID-19 Vaccine May Be More Effective for Cancer PatientsApril 29th, 2022
CLL: Undetectable Disease Likely with Ibrutinib plus VenetoclaxDecember 14th, 2021
Join now to see all